Birgitte Fagerlund

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9358534/birgitte-fagerlund-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers2,621
citations30
h-index47
g-index137
ext. papers3,358
ext. citations4.6
avg, IF5.31
L-index

#	Paper	IF	Citations
119	Early Antipsychotic Non-response as a Predictor of Non-response and Non-remission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022 ,	7.2	1
118	Effects of prenatal nutrient supplementation and early life exposures on neurodevelopment at age 10: a randomised controlled trial - the COPSYCH study protocol <i>BMJ Open</i> , 2022 , 12, e047706	3	
117	A nation-wide twin study of social cognition in schizophrenia spectrum disorders <i>NPJ Schizophrenia</i> , 2022 , 8, 12	5.5	O
116	Cortico-cognition Coupling in Treatment Resistant Schizophrenia. NeuroImage: Clinical, 2022, 103064	5.3	
115	Differential effects of age at illness onset on verbal memory functions in antipsychotic-nalle schizophrenia patients aged 12-43 years. <i>Psychological Medicine</i> , 2021 , 51, 1570-1580	6.9	9
114	CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 667-672	1.7	1
113	Association of neurocognitive functioning with sleep stage dissociation and REM sleep instability in medicated patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2021 , 136, 198-203	5.2	1
112	Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-nalle adult ADHD patients. <i>European Neuropsychopharmacology</i> , 2021 , 46, 83-92	1.2	О
111	Associations between cognition and white matter microstructure in first-episode antipsychotic-nalle patients with schizophrenia and healthy controls: A multivariate pattern analysis. <i>Cortex</i> , 2021 , 139, 282-297	3.8	1
110	Multimodal assessment of white matter microstructure in antipsychotic-nalle schizophrenia patients and confounding effects of recreational drug use. <i>Brain Imaging and Behavior</i> , 2021 , 15, 36-48	4.1	3
109	Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Nalle Patients With Schizophrenia or Psychosis. <i>Biological Psychiatry</i> , 2021 , 89, 278-287	7.9	11
108	Generalized neurocognitive impairment in individuals at ultra-high risk for psychosis: The possible key role of slowed processing speed. <i>Brain and Behavior</i> , 2021 , 11, e01962	3.4	3
107	Fish Oil Supplementation in Pregnancy and Neurodevelopment in Childhood-A Randomized Clinical Trial. <i>Child Development</i> , 2021 , 92, 1624-1635	4.9	1
106	Effects of methylphenidate on mismatch negativity and P3a amplitude of initially psychostimulant-nalle, adult ADHD patients. <i>Psychological Medicine</i> , 2021 , 1-9	6.9	0
105	Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra-high risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2021 , 144, 448-463	6.5	2
104	Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2021 , 237, 192-201	3.6	0
103	Heritability of Memory Functions and Related Brain Volumes: A Schizophrenia Spectrum Study of 214 Twins. <i>Schizophrenia Bulletin Open</i> , 2020 , 1,	2.2	2

102	Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. <i>Frontiers in Pharmacology</i> , 2020 , 11, 591	5.6	7
101	Associations between facial affect recognition and neurocognition in subjects at ultra-high risk for psychosis: A case-control study. <i>Psychiatry Research</i> , 2020 , 290, 112969	9.9	2
100	Discovering correlates of age-related decline in a healthy late-midlife male birth cohort. <i>Aging</i> , 2020 , 12, 16709-16743	5.6	О
99	Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder. <i>Neuropsychopharmacology</i> , 2020 , 45, 649-655	8.7	1
98	Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: a pilot study exploring a new tool for assessing aspects of antipsychotic-induced parkinsonism. <i>Child and Adolescent Mental Health</i> , 2020 , 25, 79-94	2.2	
97	Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. <i>Biological Psychiatry:</i> Cognitive Neuroscience and Neuroimaging, 2020, 5, 569-579	3.4	7
96	T46. THE EFFECT OF COMPREHENSIVE COGNITIVE REMEDIATION IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS: A SINGLE-BLIND, RANDOMISED, CLINICAL TRIAL (FOCUS). <i>Schizophrenia Bulletin</i> , 2020 , 46, S249-S249	1.3	78
95	T60. GENETIC INFLUENCES ON MEMORY FUNCTIONS AND RELATED BRAIN STRUCTURES AND ASSOCIATIONS WITH SCHIZOPHRENIA SPECTRUM DISORDERS: A NATION-WIDE TWIN STUDY. <i>Schizophrenia Bulletin</i> , 2020 , 46, S254-S254	1.3	78
94	Effectiveness of cognitive remediation in the ultra-high risk state for psychosis. <i>World Psychiatry</i> , 2020 , 19, 401-402	14.4	7
93	Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial. <i>Schizophrenia Research</i> , 2020 , 224, 151-158	3.6	10
92	No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis-A Randomized Clinical Trial. <i>Frontiers in Psychiatry</i> , 2020 , 11, 873	5	4
91	Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12[months. <i>European Psychiatry</i> , 2020 , 63, e83	6	3
90	Interview and questionnaire assessment of cognitive impairment in subjects at ultra-high risk for psychosis: Associations with cognitive test performance, psychosocial functioning, and positive symptoms. <i>Psychiatry Research</i> , 2020 , 294, 113498	9.9	3
89	A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-nalle schizophrenia patients based on multimodal neuropsychiatric data. <i>Translational Psychiatry</i> , 2020 , 10, 276	8.6	7
88	Heritability of specific cognitive functions and associations with schizophrenia spectrum disorders using CANTAB: a nation-wide twin study. <i>Psychological Medicine</i> , 2020 , 1-14	6.9	6
87	Do young adolescents with first-episode psychosis or ADHD show sensorimotor gating deficits?. <i>Psychological Medicine</i> , 2020 , 50, 607-615	6.9	3
86	Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disorders. <i>Psychological Medicine</i> , 2020 , 50, 1475-1489	6.9	9
85	T88. THE IMPACT OF AGE OF ONSET AND ILLNESS DURATION ON WHITE MATTER AND COGNITION TRAJECTORIES IN SCHIZOPHRENIA: A 7-YEAR FOLLOW-UP STUDY ACROSS MULTIPLE TIME-POINTS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S237-S238	1.3	78

84	T97. PATTERNS OF COGNITIVE FUNCTION ARE UNIQUELY ASSOCIATED WITH WHITE MATTER-MICROSTRUCTURE IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S241-S242	1.3	78
83	S15. HERITABILITY AND CORRELATION TO SCHIZOPHRENIA SPECTRUM DISORDERS OF CEREBRAL BLOOD FLOW MEASURED BY PSEUDO-CONTINUOUS ARTERIAL SPIN LABELING IN DANISH TWINS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S311-S311	1.3	78
82	O4.5. EXPLORING THE RELATIONSHIP BETWEEN SENSORY FILTERING AND COGNITION: RESULTS OF A LARGE COHORT OF ANTIPSYCHOTIC-NAME FIRST-EPISODE SCHIZOPHRENIA PATIENTS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S170-S171	1.3	1
81	O12.1. CARDIOMETABOLIC ADVERSE EFFECTS AND ITS PREDICTORS IN CHILDREN AND ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS DURING TREATMENT WITH QUETIAPINE-ER VERSUS ARIPIPRAZOLE: 12-WEEK RESULTS: FROM THE TEA TRIAL. <i>Schizophrenia Bulletin</i> , 2019 , 45, S1	1.3 97-S19	78 7
80	Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra-high risk for psychosis. <i>Human Brain Mapping</i> , 2019 , 40, 5185-5201	5.9	13
79	4.1 COGNITIVE RESERVE ATTENUATES AGE-RELATED COGNITIVE DECLINE IN THE CONTEXT OF ACCELERATED BRAIN AGEING IN SCHIZOPHRENIA-SPECTRUM DISORDERS: EVIDENCE FOR ACTIVE COMPENSATION. <i>Schizophrenia Bulletin</i> , 2019 , 45, S91-S92	1.3	1
78	Attenuated mismatch negativity in patients with first-episode antipsychotic-naive schizophrenia using a source-resolved method. <i>NeuroImage: Clinical</i> , 2019 , 22, 101760	5.3	6
77	O4.6. HERITABILITY OF SPECIFIC COGNITIVE FUNCTIONS AND ASSOCIATIONS WITH SCHIZOPHRENIA SPECTRUM DISORDERS USING CANTAB: A NATION-WIDE TWIN STUDY. <i>Schizophrenia Bulletin</i> , 2019 , 45, S171-S171	1.3	О
76	Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With	7.2	10
75	Cortical structures and their clinical correlates in antipsychotic-name schizophrenia patients before and after 6 weeks of dopamine D2/3 receptor antagonist treatment. <i>Psychological Medicine</i> , 2019 , 49, 754-763	62-1078 6.9	16
74	Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-nalle patients with schizophrenia. <i>European Psychiatry</i> , 2019 , 62, 130-137	6	5
73	Discovering markers of healthy aging: a prospective study in a Danish male birth cohort. <i>Aging</i> , 2019 , 11, 5943-5974	5.6	5
72	Associations between P3a and P3b amplitudes and cognition in antipsychotic-nalle first-episode schizophrenia patients. <i>Psychological Medicine</i> , 2019 , 49, 868-875	6.9	8
71	Heritability of Cerebral Blood Flow and the Correlation to Schizophrenia Spectrum Disorders: A Pseudo-continuous Arterial Spin Labeling Twin Study. <i>Schizophrenia Bulletin</i> , 2019 , 45, 1231-1241	1.3	5
70	Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-nale schizophrenia patients. <i>Psychological Medicine</i> , 2019 , 49, 2754-2763	6.9	10
69	Visual attention in adults with attention-deficit/hyperactivity disorder before and after stimulant treatment. <i>Psychological Medicine</i> , 2019 , 49, 2617-2625	6.9	5
68	Emotion recognition latency, but not accuracy, relates to real life functioning in individuals at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2019 , 210, 197-202	3.6	8
67	Sleep efficiency and neurophysiological patterns in middle-aged men are associated with cognitive change over their adult life course. <i>Journal of Sleep Research</i> , 2019 , 28, e12793	5.8	4

66	Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a [H]-spectroscopy twin study. <i>Neuropsychopharmacology</i> , 2019 , 44, 581-589	8.7	21
65	The impact of schizophrenia and intelligence on the relationship between age and brain volume. <i>Schizophrenia Research: Cognition</i> , 2019 , 15, 1-6	2.8	7
64	Patterns of Cortical Structures and Cognition in Antipsychotic-Nalle Patients With First-Episode Schizophrenia: A Partial Least Squares Correlation Analysis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019 , 4, 444-453	3.4	6
63	Hyper- and Hypomentalizing in Patients with First-Episode Schizophrenia: fMRI and Behavioral Studies. <i>Schizophrenia Bulletin</i> , 2019 , 45, 377-385	1.3	25
62	Investigation of sleep spindle activity and morphology as predictors of neurocognitive functioning in medicated patients with schizophrenia. <i>Journal of Sleep Research</i> , 2019 , 28, e12672	5.8	8
61	Overlapping and disease specific trait, response, and reflection impulsivity in adolescents with first-episode schizophrenia spectrum disorders or attention-deficit/hyperactivity disorder. <i>Psychological Medicine</i> , 2018 , 48, 604-616	6.9	7
60	Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. <i>Biological Psychiatry</i> , 2018 , 83, 492-498	7.9	205
59	Alterations of Intrinsic Connectivity Networks in Antipsychotic-Nalle First-Episode Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018 , 44, 1332-1340	1.3	13
58	Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 997-1006	5.8	8
57	Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. <i>Psychopharmacology</i> , 2018 , 235, 681-693	4.7	4
56	Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognition. <i>Schizophrenia Research</i> , 2018 , 195, 562-563	3.6	4
55	O3.3. REWARD PROCESSING AS A VULNERABILITY INDICATOR FOR PSYCHOSIS: RESULTS FROM A TWIN STUDY. <i>Schizophrenia Bulletin</i> , 2018 , 44, S80-S80	1.3	78
54	F21. ELECTROPHYSIOLOGICAL PARAMETERS OF SELECTIVE ATTENTION IN ADOLESCENTS WITH A FIRST EPISODE OF PSYCHOSIS: A COMPARISON WITH ADHD. <i>Schizophrenia Bulletin</i> , 2018 , 44, S226-S22	7 ^{1.3}	78
53	F34. AUDITORY SENSORY GATING IN YOUNG ADOLESCENTS WITH EARLY-ONSET PSYCHOSIS: A COMPARISON WITH ADHD. <i>Schizophrenia Bulletin</i> , 2018 , 44, S232-S232	1.3	78
52	F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAME SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST. <i>Schizophrenia Bulletin</i> , 2018 , 44, S289-S289	1.3	78
51	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 136, 52-62	6.5	24
50	Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. <i>Translational Psychiatry</i> , 2017 , 7, e1087	8.6	25
49	Is an Early Age at Illness Onset in Schizophrenia Associated With Increased Genetic Susceptibility? Analysis of Data From the Nationwide Danish Twin Register. <i>EBioMedicine</i> , 2017 , 18, 320-326	8.8	14

48	Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. <i>Lancet Psychiatry,the</i> , 2017 , 4, 605-618	23.3	33
47	Mismatch negativity and P3a amplitude in young adolescents with first-episode psychosis: a comparison with ADHD. <i>Psychological Medicine</i> , 2017 , 47, 377-388	6.9	19
46	Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 135, 250-258	6.5	17
45	SA37. Cognition and White Matter Integrity in Antipsychotic-Naive First-Episode Schizophrenia Patients. <i>Schizophrenia Bulletin</i> , 2017 , 43, S126-S127	1.3	78
44	SNo cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophreniaS authorsSresponse. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 136, 526-527	6.5	
43	48. Associations Between Electrophysiological Measures of Selective Attention and Neurocognitive Measures of Working Memory and Attention in Antipsychotic-Naive, First-Episode Schizophrenia Patients. <i>Schizophrenia Bulletin</i> , 2017 , 43, S26-S26	1.3	78
42	Testing a decadesSold assumption: Are individuals with lower sensory gating indeed more easily distracted?. <i>Psychiatry Research</i> , 2017 , 255, 387-393	9.9	3
41	The effect of positive symptoms on social cognition in first-episode schizophrenia is modified by the presence of negative symptoms. <i>Neuropsychology</i> , 2017 , 31, 209-219	3.8	29
40	Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience,	5.1	22
39	Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II). <i>BMJ, The</i> , 2017 , 356, i6681	5.9	53
38	Passive Double-Sensory Evoked Coherence Correlates with Long-Term Memory Capacity. <i>Frontiers in Human Neuroscience</i> , 2017 , 11, 598	3.3	4
37	Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, e1035-e1046	4.6	25
36	Subjective sleep quality and daytime sleepiness in late midlife and their association with age-related changes in cognition. <i>Sleep Medicine</i> , 2016 , 17, 165-73	4.6	38
35	Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. <i>International Journal of Neuropsychopharmacology</i> , 2016 , 19,	5.8	14
34	Melatonin and cortisol profiles in late midlife and their association with age-related changes in cognition. <i>Nature and Science of Sleep</i> , 2016 , 8, 47-53	3.6	24
33	Cognitive Change during the Life Course and Leukocyte Telomere Length in Late Middle-Aged Men. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 300	5.3	9
32	Are Weight Status and Cognition Associated? An Examination of Cognitive Development in Children and Adolescents with Anorexia Nervosa 1 Year after First Hospitalisation. <i>European Eating Disorders Review</i> , 2016 , 24, 366-76	5.3	13
31	Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10years after baseline: The OPUS study. <i>Schizophrenia Research</i> , 2016 , 175, 57-63	3.6	48

(2011-2016)

30	Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning?. <i>Schizophrenia Research: Cognition</i> , 2016 , 5, 21-27	2.8	37
29	The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. <i>Trials</i> , 2015 , 16, 25	2.8	32
28	Cognitive profile of children and adolescents with anorexia nervosa. <i>European Eating Disorders Review</i> , 2015 , 23, 34-42	5.3	38
27	Increased deoxythymidine triphosphate levels is a feature of relative cognitive decline. <i>Mitochondrion</i> , 2015 , 25, 34-7	4.9	8
26	Association Study of CHRNA7 Promoter Variants with Sensory and Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A Danish Case-Control Study. <i>NeuroMolecular Medicine</i> , 2015 , 17, 423-30	4.6	17
25	Influence of early life characteristics on psychiatric admissions and impact of psychiatric disease on inflammatory biomarkers and survival: a Danish cohort study. <i>World Psychiatry</i> , 2015 , 14, 364-5	14.4	6
24	Social cognition and neurocognitive deficits in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2014 , 153, 9-17	3.6	60
23	Cognitive function in idiopathic intracranial hypertension: a prospective case-control study. <i>BMJ Open</i> , 2014 , 4, e004376	3	45
22	Association of the CHRNA7 promoter variant -86T with Tourette syndrome and comorbid obsessive-compulsive disorder. <i>Psychiatry Research</i> , 2014 , 219, 710-1	9.9	1
21	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonistprotocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. <i>BMJ Open</i> , 2014 , 4, e004158	3	16
20	Subclinical cognitive decline in middle-age is associated with reduced task-induced deactivation of the brains default mode network. <i>Human Brain Mapping</i> , 2014 , 35, 4488-98	5.9	40
19	Quetiapine versus aripiprazole in children and adolescents with psychosisprotocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. <i>BMC Psychiatry</i> , 2014 , 14, 199	4.2	10
18	The relationship between cognitive ability and demographic factors in late midlife. <i>Journal of Aging and Health</i> , 2014 , 26, 37-53	2.6	38
17	The influence of impaired processing speed on cognition in first-episode antipsychotic-nalle schizophrenic patients. <i>European Psychiatry</i> , 2013 , 28, 332-9	6	33
16	Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , 2013 , 16, 23-36	5.8	17
15	Profile of cognitive deficits and associations with depressive symptoms and intelligence in chronic early-onset schizophrenia patients. <i>Scandinavian Journal of Psychology</i> , 2013 , 54, 363-70	2.2	4
14	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <i>BMC Medicine</i> , 2012 , 10, 92	11.4	19
13	Stability of prepulse inhibition and habituation of the startle reflex in schizophrenia: a 6-year follow-up study of initially antipsychotic-naive, first-episode schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 913-25	5.8	26

12	Cognitive effects of six months of treatment with quetiapine in antipsychotic-nalle first-episode schizophrenia. <i>Psychiatry Research</i> , 2011 , 187, 49-54	9.9	18
11	Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. <i>BMC Psychiatry</i> , 2011 , 11, 160	4.2	14
10	Course of intelligence deficits in early onset, first episode schizophrenia: a controlled, 5-year longitudinal study. <i>European Child and Adolescent Psychiatry</i> , 2010 , 19, 341-51	5.5	15
9	Deficient maturation of aspects of attention and executive functions in early onset schizophrenia. <i>European Child and Adolescent Psychiatry</i> , 2010 , 19, 773-86	5.5	2 0
8	Do attention deficits influence IQ assessment in children and adolescents with ADHD?. <i>Journal of Attention Disorders</i> , 2009 , 12, 551-62	3.7	58
7	EXTRASTRIATAL DOPAMINE D2 RECEPTOR BINDING POTENTIALS IN ANTIPSYCHOTIC-NAI/E FIRST-EPISODE SCHIZOPHRENIC PATIENTS. <i>Schizophrenia Research</i> , 2008 , 102, 42	3.6	
6	Structural brain abnormalities in early onset first-episode psychosis. <i>Journal of Neural Transmission</i> , 2007 , 114, 489-98	4.3	35
5	Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. <i>Clinical Neuropharmacology</i> , 2007 , 30, 3-12	1.4	47
4	Cognitive deficits and levels of IQ in adolescent onset schizophrenia and other psychotic disorders. <i>Schizophrenia Research</i> , 2006 , 85, 30-9	3.6	57
3	Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. <i>CNS Spectrums</i> , 2004 , 9, 364-74	1.8	43
2	The relative and interactive impact of multiple risk factors in schizophrenia spectrum disorders: a combined register-based and clinical twin study. <i>Psychological Medicine</i> ,1-11	6.9	1
1	Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. <i>Nordic Journal of Psychiatry</i> ,1-6	2.3	